The Cannasoul Group is a drug discovery company focused on developing groundbreaking therapeutics derived from natural compounds. Founded by world-renowned cannabis researcher and pioneer Prof. Dedi Meiri from the Technion – Israel Institute of Technology and backed by robust scientific capabilities, Cannasoul bridges the gap between botanical medicine and the pharmaceutical industry.
Cannasoul’s proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework support active compound identification and development, from
botanical extract through clinical approved formulation.
Pioneers in the mapping of all active compounds of the cannabis plant (cannabinoids, terpenes, flavonoids) and now developing analytical methods for psilocybin mushrooms. CannaSoul’s analytical expertise is essential for developing plant derived pharmaceutical products
Proprietary knowledge of extraction, separation, isolation and synthesis technologies that allow isolation of specific compounds from the cannabis plant, including the isolation of rare and minor cannabinoids and synthesis and modification of such molecules for further research
CannaSoul’s library of minor rare cannabinoids and synthesized novel molecules enable discovering the therapeutic effect of new unresearched molecules serving as a intellectual property pipeline for future projects
CannaSoul engages in screening of cannabis and psilocybin extracts, isolated cannabinoids and novel molecules on various cell line models at CannaSoul’s subsidiary, MyPlant Bio
7 Helix Bio, an additional subsidiary of CannaSoul, is conducting research on the endo-cannabinoid system (ECS) and developing a diagnostic tool for profiling a patient’s ECS aiming to allow personalized medicine
Utilizing data, technology, advanced analytics, and human expertise, CannaSoul’s pre-clinical and clinical activities are aimed toward developing scientifically proven cannabis-based medicine
CannaSoul has collected thousands of data points from external sources and from its proprietary database which has collected, in collaboration with Prof. Meiri’s lab at the Technion, information from over 6,000 medical cannabis patients in Israel over several years
